Modern medicine frequently presents a dilemma: a new treatment may be clinically superior to the existing standard but carries a significantly higher price tag. To determine if this additional cost is a justifiable investment, researchers use the Incremental Cost-Effectiveness Ratio (ICER). This metric provides a standardized way to compare the value of competing interventions by quantifying the cost required to achieve one additional unit of health benefit.
The Core Mechanism of Value
The ICER is calculated by dividing the difference in total costs between two interventions by the difference in their health outcomes. As Zhang and Griffin explain, this allows for the comparative ranking of different treatments against a specific "willingness-to-pay" threshold.
The formula essentially asks: How much extra are we paying for each additional unit of health we gain?
This health benefit is most commonly measured in Quality-Adjusted Life Years (QALYs). A QALY combines both the quantity of life (survival time) and the quality of that life (functional status) into a single number. For example, Schwarting and Froelich demonstrate how clinical outcomes from stroke treatments are converted into utility weights using scales like the modified Rankin Scale to calculate QALYs. By normalizing disparate clinical successes—such as preventing a stroke versus treating hepatitis C—into the common currency of QALYs, the authors can compare the economic efficiency of entirely different fields of medicine.
Determining Economic Viability
Once an ICER is calculated, it must be compared against a benchmark to decide if the intervention is "cost-effective." These benchmarks, or willingness-to-pay (WTP) thresholds, often reflect a society's wealth or healthcare budget.
- Threshold Benchmarks: In the United States, a common threshold is $150,000 per QALY. [Zhang and Bensimon](/work/cost-effectiveness-analysis-of-pembrolizumab-as-an-adjuvant-c6up) found that adjuvant pembrolizumab for melanoma fell well within this, at roughly $68,736 per QALY. Conversely, Ye et al. found that a combination therapy for mesothelioma cost over $372,000 per QALY, suggesting it is not currently sustainable at market prices.
- Regional Context: Thresholds vary by geography. Kuntjoro et al. note that thresholds are often tied to a region's per-capita Gross Domestic Product (GDP), making an intervention that is cost-effective in Singapore potentially unaffordable in a developing economy.
Dominance and Sensitivity
In the best-case scenario, a new intervention is found to be "dominant." This occurs when a treatment is both more effective and less expensive than the alternative. Yang identified perinatal depression screening as a dominant strategy in China, as it improved health outcomes while reducing total long-term costs. Similarly, Schwarting et al. found that endovascular thrombectomy for certain strokes can be dominant by significantly reducing disability-related care costs.
However, these calculations are often sensitive to specific variables, such as drug pricing or diagnostic accuracy. Sensitivity analysis allows researchers to identify the exact conditions under which a strategy remains the best choice. For instance, Chan et al. used sensitivity analysis to show that the cost-effectiveness of a specific arthritis drug reversed depending on the fluctuating price of protective co-medications.
Modeling Long-Term Impact
Because clinical trials rarely last long enough to capture a patient's entire lifetime, researchers use probabilistic models to project long-term costs and benefits.
- Markov Models: These models simulate patients moving through different "health states" over time. Arias et al. describe tools like OpenMarkov that facilitate these complex simulations.
- Diagnostic Efficiency: Beyond QALYs, cost-effectiveness can be measured by the cost per case detected. Hu evaluated diagnostic tools for urinary calculi by balancing inspection fees against detection rates, while He et al. proposed "entropy removal" to measure how much uncertainty a test eliminates relative to its cost.
By integrating clinical data with economic modeling, the ICER framework moves healthcare decision-making away from intuition and toward a rigorous, evidence-based allocation of limited resources.
Key Foundational Work
Prevention of ulcer bleeding in high-risk patients: is the enthusiasm for COX-2 selective NSAIDs justified? (2007) — contributed 1 concept elements to this direction.
Supplier Selection Based on Process Capability and Price Analysis (2006) — contributed 1 concept elements to this direction.